retatrutide weight loss trial Phase III study demonstrates 30% Eli Lilly's Next-Gen Obesity Drug

Semaglutide is a GLP-1 receptor agonist, while Tirzepatide targets both GLP-1 and GIP pathways, offering slightly faster weight loss for some patients

They are not designed to diagnose, treat, cure or prevent any disease

Nat Rev Endocrinol 8:728742

Phase 2 Trial Adverse Event Data (NEJM, 2023) The pivotal Phase 2 trial (n=338) randomized participants across multiple dose levels over 48 weeks

Water, thickener (locust bean gum), nicotinamide (niacin), riboflavin (riboflavin-5-sodium phosphate), vitamin B6 1.40 mg (pyridoxine hydrochloride), thiamine (thiamine hydrochloride), biotin, vitamin B12 (methylcobalamin), natural flavours